Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BNT 142

Next Previous
Drug Profile

BNT 142

Alternative Names: BNT-142

Latest Information Update: 01 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioNTech
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; RNA
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 28 Mar 2022 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in USA (IV) (NCT05262530)
  • 09 Nov 2021 BioNTech plans a phase I trial in Solid tumours in the first half of 2022
  • 25 Nov 2020 BioNtech and InstaDeep agree to co-develop RiboMab platform based BNT 142 for Cancer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top